Can obesity pharmacotherapy modify osteoarthritis? Interpreting pain relief, weight-loss quality, and structural outcomes.

Abstract

Objective: To evaluate the emerging role of obesity pharmacotherapies, particularly glucagon-like peptide-1 (GLP-1) receptor agonists and multi-agonists, in osteoarthritis (OA) management, by examining the interpretation of pain outcomes, potential structural joint effects, the importance of weight-loss quality, implications for time to total joint replacement (TJR), and the patient populations most likely to benefit from current obesity pharmacotherapies.

Methods: We conducted a narrative review of clinical and basic science literature examining the relationships between obesity, OA, and weight loss, with a particular focus on GLP-1 therapies and emerging obesity medications. Evidence from randomized controlled trials, observational studies, translational investigations, and regulatory guidance documents was reviewed with emphasis on pain outcomes, structural joint effects, and factors influencing progression to TJR.

Results: Recent randomized controlled trials, primarily involving patients with OA and class III obesity (body mass index >40), demonstrate substantial pain reduction following obesity pharmacotherapy. However, interpretation of these benefits is complicated by obesity-associated pain, multimorbidity, and limitations of patient-reported outcomes such as WOMAC. Current evidence supports symptomatic improvement associated with weight loss, but whether obesity pharmacotherapies directly modify OA-related pain pathways or slow structural progression remains unknown. Moreover, the quality of weight loss may be important, as reductions in fat mass may be accompanied by bone loss and reduced muscle mass. Patients at heightened risk of structural deterioration, such as sarcopenia or elevated bone resorption, may be particularly vulnerable to these effects. Emerging concepts such as clinical obesity further highlight the biological heterogeneity of OA populations and suggest that treatment responses may differ considerably between patients.

Conclusions: In the absence of evidence demonstrating direct joint structural modification, obesity pharmacotherapies cannot currently be considered disease-modifying OA treatments. Nonetheless, they may set a new benchmark for pain management in selected OA patients living with obesity. Because weight loss may not necessarily translate to structural benefit despite symptomatic improvement, pain should not serve as a stand-alone outcome in OA-obesity trials. Future studies should evaluate structural outcomes, weight-loss quality, and patient heterogeneity to ensure that obesity therapies deliver sustained symptomatic benefits in OA without compromising musculoskeletal health.